SCHEMBL4325933

SCHEMBL4325933

N=C(N)N[C@@H](CCCCNC(=O)Cc1ccc(OCc2ccccc2)cc1)C(N)=O

nearest known ligand 0.50

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
EPOR P19235 5/20 0.48
PPARG P37231 1/20 0.47
CHRM4 P08173 1/20 0.46
KCNH2 Q12809 2/20 0.46
SIRT2 Q8IXJ6 1/20 0.46
GRIN1 Q05586 1/20 0.46
GRIN2A Q12879 1/20 0.46
HDAC1 Q13547 1/20 0.46
HDAC7 Q8WUI4 1/20 0.46
TRPV1 Q8NER1 1/20 0.45
CTSL P07711 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL4327980 0.94 PPARG (0.45) EPORPPARGCHRM4KCNH2SIRT2
SCHEMBL4320367 0.84 LTA4H (0.59) EPORCHRM4KCNH2HDAC1HDAC7
SCHEMBL4327986 0.82 KCNH2 (0.45) EPORCHRM4KCNH2HDAC1HDAC7
SCHEMBL4320373 0.80 EPOR (0.52) EPORCHRM4KCNH2HDAC1HDAC7
Trifluoroacetic Acid SCHEMBL4320176 0.79 LTA4H (0.53) EPORCHRM4KCNH2HDAC1HDAC7
SCHEMBL2076563 0.77 KCNH2 (0.67) EPORCHRM4KCNH2
SCHEMBL7653534 0.76 GPR34 (0.57)
Trifluoroacetic Acid SCHEMBL4320181 0.75 CHRM4 (0.48) EPORCHRM4KCNH2HDAC1HDAC7
SCHEMBL4320178 0.74 CHRM4 (0.47) EPORCHRM4KCNH2HDAC1HDAC7
SCHEMBL4327813 0.74 LTA4H (0.60) EPOR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009138378-A1 3,5-DIAMINO-6-CHLORO-PYRAZINE-2-CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS EPITHELIAL SODIUM CHANNEL BLOCKERS FOR THE TREATMENT OF ARWAY DISEASES NOVARTIS AG (CH) 2009-11-19 WO claimed
US-8664228-B2 3,5-diamino-6-chloro-pyrazine-2-carboxylic acid derivatives and their use as epithelial sodium channel blockers for the treatment of airway diseases NOVARTIS AG (CH) 2014-03-04 US disclosed
WO-2009138378-A1 3,5-DIAMINO-6-CHLORO-PYRAZINE-2-CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS EPITHELIAL SODIUM CHANNEL BLOCKERS FOR THE TREATMENT OF ARWAY DISEASES NOVARTIS AG (CH) 2009-11-19 WO disclosed